Precigen's PAPZIMEOS FDA Approval Drives Stock Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 15 2025
0mins
Should l Buy PGEN?
Precigen Inc's stock surged by 27.74% as it crossed above the 5-day SMA, reflecting strong market interest following the FDA approval of its product PAPZIMEOS.
The company reported that PAPZIMEOS received FDA approval for treating recurrent respiratory papillomatosis, marking a significant transition to commercial sales with first revenues of $3.4 million. This approval has garnered robust support from the medical community, with over 300 patient enrollments, indicating a successful market entry and potential for future growth. Additionally, the CEO projected optimistic revenue forecasts for Q1 2026, further boosting investor confidence.
This positive momentum suggests that Precigen is on a path to capitalize on its recent FDA approval, with expectations of increased market share and revenue growth, despite facing challenges in managing operational expenses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PGEN
Wall Street analysts forecast PGEN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.100
Low
9.00
Averages
9.00
High
9.00
Current: 3.100
Low
9.00
Averages
9.00
High
9.00
About PGEN
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Precigen Q4 2025 Earnings Call Highlights
- Revenue Growth: Precigen reported $3.4 million in product revenue for Q4 2025, with shipments starting in November, and expects Q1 2026 revenues to exceed $18 million, indicating strong market demand and product acceptance.
- Broad Payer Coverage: As of early January, Precigen's payer coverage increased from approximately 170 million to 215 million lives, encompassing nearly all major commercial, Medicare, and Medicaid payers, enhancing the product's market penetration capabilities.
- Significant Financial Improvement: Total revenue for 2025 reached $9.7 million, a 149% increase from 2024, despite a net loss of $429.6 million; however, management anticipates achieving cash flow breakeven by the end of 2026, indicating progress towards profitability.
- Clinical Trials and Expansion Plans: Management announced plans to initiate a PAPZIMEOS clinical trial for pediatric RRP in Q4 2026 and is pursuing EMA marketing authorization, demonstrating the company's strategic focus on new markets and indications.
See More
Precigen Shares Surge 30% on Positive Q1 Revenue Outlook Despite Lower Financials
- Financial Overview: Precigen reported Q4 revenue of $9.7 million, missing market expectations by $3.8 million, although product revenue from Papzimeos reached $3.4 million, indicating the new therapy's market potential.
- Widened Net Loss: The company's net loss per share widened approximately 191% year-over-year to $1.37, primarily due to a 70% year-over-year surge in selling and administrative expenses to $70.1 million, including $27.3 million related to the Papzimeos launch.
- Optimistic Revenue Forecast: CEO Helen Sabzevari projected Q1 revenue could exceed $18 million, surpassing Bloomberg's consensus of $14.1 million, reflecting strong demand from patients and physicians for Papzimeos.
- Analyst Rating Upgrades: H.C. Wainwright analyst raised the price target from $9 to $10, believing Papzimeos has the potential to become a franchise product, demonstrating market confidence in its future growth.
See More
Precigen Inc Reports Strong Revenue Growth and Challenges in 2025 Earnings
- Significant Revenue Growth: Precigen Inc reported a net product revenue of $3.4 million in Q4 2025, with full-year revenue reaching $9.7 million, a 149% increase year-over-year, and expects Q1 2026 revenue to exceed $18 million, indicating a successful transition from R&D to commercialization.
- FDA Approval of New Drug: The company’s PAPZIMEOS received full FDA approval for adult recurrent respiratory papillomatosis, reflecting unmatched efficacy and strong clinical data, which is expected to further drive revenue growth and expand market share.
- Expense Structure Changes: While research and development expenses decreased by $11.7 million (22.1%) from 2024, selling, general, and administrative expenses increased by $28.8 million (69.8%), primarily due to costs associated with PAPZIMEOS commercial activities, potentially impacting future profitability.
- Patient Conversion Challenges: The company faces challenges in converting 300 patients from the support hub to receiving reimbursed treatment; although the J-code simplifies the process, the speed of conversion varies by institution, which may affect the sustainability of revenue.
See More
Precigen (PGEN) Q4 2025 Earnings Call Transcript
See More
Precigen Reports 2025 Financial Results and Product Updates
- FDA Approval Transition: In 2025, Precigen received FDA approval for PAPZIMEOS, marking a transition from clinical to commercial stage with first product revenues of $3.4 million, indicating strong market demand and successful strategic transformation.
- Market Acceptance Growth: As the first-line treatment for adults with recurrent respiratory papillomatosis, PAPZIMEOS has gained robust support from the physician community, with over 300 patient enrollments reflecting significant progress in expanding market share and enhancing brand recognition.
- Financial Condition Changes: Total revenues increased by $5.8 million in 2025 compared to 2024, primarily driven by PAPZIMEOS commercial sales, while R&D expenses decreased by $11.7 million; however, SG&A expenses surged by $28.8 million due to aggressive commercialization efforts.
- Net Loss Expansion: Precigen reported a net loss of $429.6 million in 2025, a 303.4% increase from 2024, primarily due to non-cash dividends on preferred stock and increased fair value of warrant liabilities, highlighting challenges in financial management and profitability.
See More
Precigen Reports FY Non-GAAP EPS of -$1.37 with Revenue Growth
- Earnings Overview: Precigen reported a FY Non-GAAP EPS of -$1.37, with revenue reaching $9.7 million, reflecting a significant year-over-year growth of 148.7%, yet it fell short of expectations by $3.83 million, indicating ongoing challenges in profitability.
- Revenue Growth Analysis: Despite the substantial revenue increase, Precigen's $9.7 million revenue did not meet market expectations, suggesting potential shortcomings in product marketing and sales strategies that could impact overall financial performance.
- Market Reaction: The failure to meet revenue targets may pressure Precigen's stock price, prompting investors to closely monitor the company's future strategic adjustments and market performance.
- Future Outlook: At the upcoming J.P. Morgan Healthcare Conference, Precigen is expected to outline its strategic plans and product development progress, aiming to restore investor confidence and drive stock price recovery.
See More
Precigen Q4 2025 Earnings Call Highlights
- Revenue Growth: Precigen reported $3.4 million in product revenue for Q4 2025, with shipments starting in November, and expects Q1 2026 revenues to exceed $18 million, indicating strong market demand and product acceptance.
- Broad Payer Coverage: As of early January, Precigen's payer coverage increased from approximately 170 million to 215 million lives, encompassing nearly all major commercial, Medicare, and Medicaid payers, enhancing the product's market penetration capabilities.
- Significant Financial Improvement: Total revenue for 2025 reached $9.7 million, a 149% increase from 2024, despite a net loss of $429.6 million; however, management anticipates achieving cash flow breakeven by the end of 2026, indicating progress towards profitability.
- Clinical Trials and Expansion Plans: Management announced plans to initiate a PAPZIMEOS clinical trial for pediatric RRP in Q4 2026 and is pursuing EMA marketing authorization, demonstrating the company's strategic focus on new markets and indications.
See More
Precigen Shares Surge 30% on Positive Q1 Revenue Outlook Despite Lower Financials
- Financial Overview: Precigen reported Q4 revenue of $9.7 million, missing market expectations by $3.8 million, although product revenue from Papzimeos reached $3.4 million, indicating the new therapy's market potential.
- Widened Net Loss: The company's net loss per share widened approximately 191% year-over-year to $1.37, primarily due to a 70% year-over-year surge in selling and administrative expenses to $70.1 million, including $27.3 million related to the Papzimeos launch.
- Optimistic Revenue Forecast: CEO Helen Sabzevari projected Q1 revenue could exceed $18 million, surpassing Bloomberg's consensus of $14.1 million, reflecting strong demand from patients and physicians for Papzimeos.
- Analyst Rating Upgrades: H.C. Wainwright analyst raised the price target from $9 to $10, believing Papzimeos has the potential to become a franchise product, demonstrating market confidence in its future growth.
See More
Precigen Inc Reports Strong Revenue Growth and Challenges in 2025 Earnings
- Significant Revenue Growth: Precigen Inc reported a net product revenue of $3.4 million in Q4 2025, with full-year revenue reaching $9.7 million, a 149% increase year-over-year, and expects Q1 2026 revenue to exceed $18 million, indicating a successful transition from R&D to commercialization.
- FDA Approval of New Drug: The company’s PAPZIMEOS received full FDA approval for adult recurrent respiratory papillomatosis, reflecting unmatched efficacy and strong clinical data, which is expected to further drive revenue growth and expand market share.
- Expense Structure Changes: While research and development expenses decreased by $11.7 million (22.1%) from 2024, selling, general, and administrative expenses increased by $28.8 million (69.8%), primarily due to costs associated with PAPZIMEOS commercial activities, potentially impacting future profitability.
- Patient Conversion Challenges: The company faces challenges in converting 300 patients from the support hub to receiving reimbursed treatment; although the J-code simplifies the process, the speed of conversion varies by institution, which may affect the sustainability of revenue.
See More
Precigen (PGEN) Q4 2025 Earnings Call Transcript
See More
Precigen Reports 2025 Financial Results and Product Updates
- FDA Approval Transition: In 2025, Precigen received FDA approval for PAPZIMEOS, marking a transition from clinical to commercial stage with first product revenues of $3.4 million, indicating strong market demand and successful strategic transformation.
- Market Acceptance Growth: As the first-line treatment for adults with recurrent respiratory papillomatosis, PAPZIMEOS has gained robust support from the physician community, with over 300 patient enrollments reflecting significant progress in expanding market share and enhancing brand recognition.
- Financial Condition Changes: Total revenues increased by $5.8 million in 2025 compared to 2024, primarily driven by PAPZIMEOS commercial sales, while R&D expenses decreased by $11.7 million; however, SG&A expenses surged by $28.8 million due to aggressive commercialization efforts.
- Net Loss Expansion: Precigen reported a net loss of $429.6 million in 2025, a 303.4% increase from 2024, primarily due to non-cash dividends on preferred stock and increased fair value of warrant liabilities, highlighting challenges in financial management and profitability.
See More
Precigen Reports FY Non-GAAP EPS of -$1.37 with Revenue Growth
- Earnings Overview: Precigen reported a FY Non-GAAP EPS of -$1.37, with revenue reaching $9.7 million, reflecting a significant year-over-year growth of 148.7%, yet it fell short of expectations by $3.83 million, indicating ongoing challenges in profitability.
- Revenue Growth Analysis: Despite the substantial revenue increase, Precigen's $9.7 million revenue did not meet market expectations, suggesting potential shortcomings in product marketing and sales strategies that could impact overall financial performance.
- Market Reaction: The failure to meet revenue targets may pressure Precigen's stock price, prompting investors to closely monitor the company's future strategic adjustments and market performance.
- Future Outlook: At the upcoming J.P. Morgan Healthcare Conference, Precigen is expected to outline its strategic plans and product development progress, aiming to restore investor confidence and drive stock price recovery.
See More
